Education Program
Acute Myeloid Malignancies, AML, Diseases, Therapies, Myeloid Malignancies, Technology and Procedures
Pacific Ballroom Salons 15-17
(Marriott Marquis San Diego Marina)
Description:
While the number of novel and effective therapies available for patients with newly diagnosed acute myeloid leukemia (AML) has increased significantly over the past 5 years, management of relapsed and refractory AML, particularly following induction with a venetoclax based regimen, remains a challenge. Moreover, the ability to measure the level of disease at the morphologic, cytogenetic, and molecular level has increased the complexity of disease assessments. Specifically, questions remain as to what should be measured when, how it should be measured, and whether this information should be used in risk stratification or when making treatment decisions. This session will explore the different technologies that are utilized for detection of measurable disease and make recommendations for how to incorporate these results into your clinical practice. This session will also address the challenge of treatment recommendations for patients who fail hypomethylating agents + venetoclax and discuss novel therapies in development, including those that are immunotherapy based.
Chair:
Alison R. Walker, MD, MPH, MBA, H.Lee Moffitt Cancer Center & Research Institute
Disclosures:
No relevant conflicts of interest to declare.
While the number of novel and effective therapies available for patients with newly diagnosed acute myeloid leukemia (AML) has increased significantly over the past 5 years, management of relapsed and refractory AML, particularly following induction with a venetoclax based regimen, remains a challenge. Moreover, the ability to measure the level of disease at the morphologic, cytogenetic, and molecular level has increased the complexity of disease assessments. Specifically, questions remain as to what should be measured when, how it should be measured, and whether this information should be used in risk stratification or when making treatment decisions. This session will explore the different technologies that are utilized for detection of measurable disease and make recommendations for how to incorporate these results into your clinical practice. This session will also address the challenge of treatment recommendations for patients who fail hypomethylating agents + venetoclax and discuss novel therapies in development, including those that are immunotherapy based.
Jacqueline Cloos, MD
Cancer Center Amsterdam, Department of Hematology, Amsterdam UMC, Location VUMC, Amsterdam, Netherlands
Marion Subklewe, MD
Department of Medicine III (Hem/Onc), Ludwig-Maximilians-University Hospital Munich, Munich, Germany
Alison R. Walker, MD, MPH, MBA
H.Lee Moffitt Cancer Center & Research Institute, Tampa, FL
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.